<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943891</url>
  </required_header>
  <id_info>
    <org_study_id>MC01/09/08</org_study_id>
    <nct_id>NCT00943891</nct_id>
  </id_info>
  <brief_title>A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer</brief_title>
  <official_title>A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To determine the association between LVD and clinico-pathologic variables in archived
           colorectal cancer and Nasopharyngeal carcinoma specimens

        2. To determine the association between VEGF-C,-D expression with COX-2 expression and
           clinico-pathologic variables in colorectal cancer and Nasopharyngeal carcinoma

        3. To determine the effect of celecoxib on lymphangiogenesis in Nasopharyngeal carcinoma
           Lymphangiogenesis and factors modulating lymphangiogenesis are associated with
           clinico-pathological outcome in Nasopharyngeal carcinoma and colorectal cancer.
           Celecoxib down-regulates lymphangiogenesis Archival colorectal cancer and Nasopharyngeal
           carcinoma tumor specimens will be obtained from the Department of Pathology. To
           determine the effect of celecoxib on lymphangiogenesis in Nasopharyngeal carcinoma, the
           investigators intend to analyze archived specimens collected in a previously conducted
           study. Colorectal tumor and nodal specimens and Nasopharyngeal carcinoma primary will be
           examined for MVD, LVD and growth factor expression using established haematoxylin and
           eosin and immunohistochemical techniques. Quantification of LVD and MVD shall be
           performed by two pathologists blinded to clinico-pathological variables using
           standardised methods.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment>500</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Nasopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Tumor biopsies</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsies</intervention_name>
    <arm_group_label>Tumor biopsies</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CRC and NPC tumor specimens will be obtained.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Colorectal and nasopharyngeal cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients are eligible

          -  Patients 21 years or older

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross Andrew Soo, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001 Feb;7(2):186-91.</citation>
    <PMID>11175849</PMID>
  </reference>
  <reference>
    <citation>Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001 Feb 15;20(4):672-82.</citation>
    <PMID>11179212</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

